Microalbuminuria as surrogate endpoint in therapeutic trials
Current Hypertension Reports, 05/14/2012
Redon J et al. – Authors review evidence regarding microalbuminuria as one potential surrogate endpoint. In diabetes, hypertension and high cardiovascular risk, recent studies have demonstrated the prognostic value of significant changes in urinary albumin excretion for cardiovascular and renal outcomes. The most appropriate timing with which to repeat microalbuminuria and whether or not changes should be targeted during the antihypertensive treatment remain unanswered.